AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL | NASDAQ
Chart Builder DCF Calculator
$12.66
+$0.03 (+0.24%)
At close: Sep 21, 2026, 4:00 PM ET
$12.69
+$0.03 (+0.24%)
Pre-market: Sep 22, 2026, 7:00 AM ET

Market Data

Market Cap
$3.87B
Enterprise Value
$3.46B
Beta
1.19
Average Volume
8.04M
Shares Outstanding (Diluted)
305.56M
Shares Change YoY
2.36%
Institutional Ownership
41.01%
Exchange
NASDAQ
ISIN
CA00288U1066

Price Performance

Price Change 1M
15.9%
Price Change 3M
124.9%
Price Change 6M
273.4%
Price Change YTD
269.1%
Price Change 1Y
162.1%
Price Change 3Y
153.2%
Price Change 5Y
-40.1%
1M CAGR (ann.)
82.7%
1Y CAGR (ann.)
168.2%
5Y CAGR (ann.)
-6.5%
All-Time CAGR
-23.4%

Valuation

PE Ratio
-23.44
Forward PE
N/A
PEG Ratio
43.16
Forward PEG
-2.52
PS Ratio
58.42
Forward PS
148.40
PB Ratio
4.31
P/FCF Ratio
-21.54
P/Adj. FCF Ratio
-16.77
P/OCF Ratio
-24.82
EV/Sales
52.31
EV/EBIT
-17.17
EV/EBITDA
-21.59
EV/FCF
-19.29
Earnings Yield
-4.3%
FCF Yield
-4.6%
Adj. FCF Yield
-6.0%

Financial Health

Net Cash
$540.1M
Total Debt
$135.62M
Cash & Short-Term Investments
$540.1M
Total Assets
$1.31B
Current Ratio
12.77
Quick Ratio
12.63
Debt / Equity Ratio
0.15
Debt / EBITDA
-0.85
Debt / FCF
-0.76
OCF / Debt
-1.14
Interest Coverage
0.00
Altman Z-Score
5.62
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
75.0%
Operating Profit Margin
-340.3%
EBITDA Margin
-242.3%
Net Profit Margin
-248.8%
FCF Margin
-271.2%
Adj. FCF Margin
-348.4%
SBC / Revenue
77.2%
SBC Impact (per share)
-28.5%

Returns

Return on Assets
-12.6%
Return on Equity
-17.5%
Return on Invested Capital
-14.9%
Return on Capital Employed
-17.9%
Return on Tangible Assets
-13.5%

Historical Growth (CAGR)

Revenue CAGR 3Y
-23.0%
Revenue CAGR 5Y
-31.8%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-0.9%
EPS CAGR 5Y
-103.5%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-3.0%
FCF CAGR 5Y
-113.0%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
12
EPS Growth Next 3Y
-16.1%
Revenue Growth Next 3Y
-4.5%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.18
EPS Growth Est (next Q)
-5.3%
Revenue Est (next Q)
$5.32M
Revenue Growth Est (next Q)
-40.5%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$15.33
Price Target Upside
21.1%

Cash Flow

Operating Cash Flow
$-154.72M
Free Cash Flow
$-179.46M
Adj. Free Cash Flow
$-230.56M
FCF Per Share
-$0.59
OCF Per Share
-$0.51
OCF/S Ratio
-233.8%

Income Statement

Revenue
$66.17M
Gross Profit
$49.6M
Operating Income
$-225.16M
EBITDA
$-160.3M
Net Income
$-164.66M
EPS (Diluted)
-$0.54
Revenue / Employee
$117.75K
Profit / Employee
$-292.98K
Employees
562

© 2026 bestshares.com. All rights reserved.